The Journal of Urology
Volume 177, Issue 1 , Pages 17-24 , January 2007

Bone Health in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

  • James A. Eastham

      Affiliations

    • Corresponding Author InformationCorrespondence and requests for reprints: Department of Urology, Memorial Sloan-Kettering Cancer Center, 353 East 68th St., Suite 527, New York, New York 10021 (telephone: 646-422-4390; FAX: 212-988-0759).

Received 23 December 2005

References 

  1. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294:238
  2. Higano CS. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin North Am. 2004;31:331
  3. Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002;167:2361
  4. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy; recommendations for diagnosis and therapies. Cancer. 2004;100:892
  5. Smith MR, Lee WC, Krupsi TL, Brandman J, Wang Q, Botteman M, et al. Association between androgen deprivation therapy and fracture risk: a population-based cohort study in men with non-metastatic prostate cancer. Proc Am Soc Clin Oncol. 2004;23:382
  6. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345:948
  7. Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS. Low bone mineral density in hormone-naïve men with prostate carcinoma. Cancer. 2001;91:2238
  8. Hussain SA, Weston R, Stephenson RN, George E, Parr NJ. Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int. 2003;92:690
  9. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154
  10. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002;168:1005
  11. Leder BZ, LeBlanc KM, Schoenfeld DA, Eastell R, Finkelstein JS. Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab. 2003;88:204
  12. Benito M, Gomberg B, Wehrli FW, Weening RH, Zemel B, Wright AC, et al. Deterioration of trabecular architecture in hypogonadal men. J Clin Endocrinol Metab. 2003;88:1497
  13. Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab. 2002;87:3656
  14. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol. 1999;161:1219
  15. Eriksson S, Eriksson A, Stege R, Carlstrom K. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int. 1995;57:97
  16. Physician’s Guide to Prevention and Treatment of Osteoporosis. Washington, D. C: National Osteoporosis Foundation; 2003;
  17. Higano CS. Management of bone loss in men with prostate cancer. J Urol, part 2. 2003;170:S59
  18. Lipton A, Costa L, Ali S, Demers L. Use of markers of bone turnover for monitoring bone metastases and the response to therapy. Semin Oncol. 2001;28:54
  19. Miller PD, Baran DT, Bilezikian JP, Greenspan SL, Lindsay R, Riggs BL, et al. Practical clinical application of biochemical markers of bone turnover: consensus of an expert panel. J Clin Densitom. 1999;2:323
  20. Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer. 1998;83:1561
  21. Faulkner KG. Bone matters: are density increases necessary to reduce fracture risk?. J Bone Miner Res. 2000;15:183
  22. López AM, Pena MA, Hernández R, Val F, Martin B, Riancho JA. Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int. 2005;16:707
  23. Kado DM, Browner WS, Palermo L, Nevitt MC, Genant HK, Cummings SR. Vertebral fractures and mortality in older women: a prospective study (Study of Osteoporotic Fractures Research Group). Arch Intern Med. 1999;159:1215
  24. Dawson NA. Therapeutic benefit of bisphosphonates in the management of prostate cancer-related bone disease. Expert Opin Pharmacother. 2003;4:705
  25. Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994;9:745
  26. Brown JE, Neville-Webbe H, Coleman RE. The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer. 2004;11:207
  27. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169:2008
  28. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879
  29. Saad F, Schulman CC. Role of bisphosphonates in prostate cancer. Eur Urol. 2004;45:26
  30. Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist. 2004;9(suppl):28
  31. Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353:99
  32. Van Poznak CH, Estilo CL, Sauter NP, Hudis CA, Williams T, Tunick S, et al. Osteonecrosis of the jaw in patients with metastatic breast cancer. San Antonio, Texas: Annual San Antonio Breast Cancer Symposium; 2004;December 8–11
  33. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23:8580
  34. Ruggiero SL, Gralow J, Marx RE, Hoff A, Schubert MM, Huryn JM, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract. 2006;2:7
  35. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 1993;11:59
  36. Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol. 1995;13:2427
  37. Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med. 1999;246:67
  38. Sebaldt RJ, Shane LG, Pham BZ, Cook RJ, Thabane L, Petrie A, et al. Impact of non-compliance and non-persistence with daily bisphosphonates on longer-term effectiveness outcomes in patients with osteoporosis. J Bone Miner Res. 2004;19(suppl):S445
  39. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89:3841
  40. Scherr DS, Pitts WR. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. J Urol. 2003;170:1703
  41. Ockrim JL, Lalani E, Kakkar AK, Abel PD. Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism. J Urol. 2005;174:527
  42. Hertel KL, Trahiotis MG. Exercise in the prevention and treatment of osteoporosis: the role of physical therapy and nursing. Nurs Clin North Am. 2001;36:441
  43. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005;293:2257
  44. Clinical Practice Guidelines in Oncology, Prostate Cancer Version 2.2005. National Comprehensive Cancer Network 2005.
  45. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004;292:490
  46. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004;19:1059
  47. Tanvetyanon T. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer. 2005;103:237
  48. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000;163:181
  49. Higano CS, Stephens C, Nelson P, Fearne V, Davies C, Russell K, et al. Prospective serial measurements of bone mineral density (BMD) in prostate cancer patients without bone metastases treated with intermittent androgen suppression (IAS). Proc Am Soc Clin Oncol. 1999;18:314
  50. Zometa® (Zoledronic Acid) Injection Prescribing Information. East Hanover, New Jersey: Novartis Pharmaceutical; 2005;

 For another article on a related topic see page 359.

PII: S0022-5347(06)02171-9

doi: 10.1016/j.juro.2006.08.089

The Journal of Urology
Volume 177, Issue 1 , Pages 17-24 , January 2007

Article Tools

* Image Usage & Resolution